Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1719-1729

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miserez, A. R.
Right arrow Articles by Keller, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miserez, A. R.
Right arrow Articles by Keller, U.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1719-1729.)
© 1995 American Heart Association, Inc.


Articles

Differences in the Phenotypic Characteristics of Subjects With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia

André R. Miserez; Ulrich Keller

From the Departments of Research and Internal Medicine, University Hospital, Basel, Switzerland.

Correspondence to A.R. Miserez, MD, Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas TX 75235-7200.

Abstract Familial defective apolipoprotein B-100 (FDB) is a recently identified autosomal-dominantly inherited disorder caused by a point mutation in the apolipoprotein (apo) B gene. To determine whether the phenotypic characteristics in FDB subjects are similar to those in subjects with familial hypercholesterolemia (FH), 76 kindreds fulfilling the clinical criteria for heterozygous FH/FDB were characterized using molecular biological techniques. Allele-specific polymerase chain reaction (PCR) at the apoB locus was used for diagnosis or exclusion of FDB. PCR-based methods for detection of two point mutations (V408M and P664L) at the LDL receptor (LDLR) locus, cosegregation analysis using eight restriction fragment length polymorphisms (RFLPs) at the LDLR locus, or the exclusion of FDB confirmed the clinical diagnosis of FH. Three kindreds were not included because of a missing cosegregation between a particular haplotype and the FH phenotype. We predicted that a similar number of kindreds would be detected in the two groups, assuming comparable prevalences of the diseases in our population and similar phenotypic characteristics. However, only nine kindreds were identified with the FDB mutation compared with 64 kindreds with FH (P<.0001). From these 73 kindreds, 28 FDB heterozygotes and 129 FH heterozygotes were compared using multivariate analysis. There were no differences between these two groups with respect to age, sex, and apoE genotype distribution, lipoprotein(a) concentrations, body mass index, blood pressure, and smoking habits. However, FDB subjects demonstrated significantly lower concentrations of total cholesterol (8.1 versus 10.2 mmol/L, P<.001), LDL cholesterol (6.3 versus 8.2 mmol/L, P<.001), and triglycerides (1.3 versus 1.8 mmol/L, P=.025) and higher concentrations of HDL cholesterol (1.4 versus 1.2 mmol/L, P=.015) than subjects with FH. In contrast to FH, female FDB subjects tended to have higher concentrations of total cholesterol (8.9 versus 7.5 mmol/L, P=.032) and LDL cholesterol (7.1 versus 5.7 mmol/L, P=.026) than FDB males. The same results regarding total and LDL cholesterol and sex differences were observed when individual data of 238 FDB and 415 FH subjects from the literature were compared. In addition, FDB subjects showed much larger total cholesterol fluctuations than FH subjects (median of intraindividual coefficients of variation: FDB, 14.5%; FH, 5.3%; P<.001). In summary, these results demonstrate that FDB subjects tend to have a milder form of hyperlipoproteinemia than FH subjects and that only a part of the subjects with FDB fulfill the established criteria for identifying FH.


Key Words: apolipoprotein B-100 • LDL receptor • mutations • genotype • phenotype




This article has been cited by other articles:


Home page
Genome ResHome page
K. K. Alharbi, M. A. Aldahmesh, E. Spanakis, L. Haddad, R. A. Whittall, X.-h. Chen, H. Rassoulian, M. J. Smith, J. Sillibourne, N. J. Ball, et al.
Mutation scanning by meltMADGE: Validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population
Genome Res., July 1, 2005; 15(7): 967 - 977.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries
Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review
Am. J. Epidemiol., September 1, 2004; 160(5): 421 - 429.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. K. Soutar, R. P. Naoumova, and L. M. Traub
Genetics, Clinical Phenotype, and Molecular Cell Biology of Autosomal Recessive Hypercholesterolemia
Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 1963 - 1970.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Jacobsen, M. Fenger, J. Bentzen, S. L. Rasmussen, M. H. Jakobsen, J. Fenstholt, and J. Skouv
Genotyping of the Apolipoprotein B R3500Q Mutation Using Immobilized Locked Nucleic Acid Capture Probes
Clin. Chem., April 1, 2002; 48(4): 657 - 660.
[Full Text] [PDF]


Home page
J. Med. Genet.Home page
P Y Muller and A R Miserez
Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterolaemic subjects
J. Med. Genet., April 1, 2002; 39(4): 271 - 275.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. E Rossouw
Hormones, genetic factors, and gender differences in cardiovascular disease
Cardiovasc Res, February 15, 2002; 53(3): 550 - 557.
[Full Text] [PDF]


Home page
BMJHome page
I. N M Day and D. I Wilson
Science, medicine, and the future: Genetics and cardiovascular risk
BMJ, December 15, 2001; 323(7326): 1409 - 1412.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J.-P. Rabes, M. Varret, M. Devillers, P. Aegerter, L. Villeger, M. Krempf, C. Junien, and Catherine Boileau
R3531C Mutation in the Apolipoprotein B Gene Is Not Sufficient to Cause Hypercholesterolemia
Arterioscler Thromb Vasc Biol, October 1, 2000; 20 (10): e76 - e82.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
U. ZUMSTEG, P. Y MULLER, and A. R MISEREZ
Alstrom syndrome: confirmation of linkage to chromosome 2p12-13 and phenotypic heterogeneity in three affected sibs
J. Med. Genet., July 1, 2000; 37(7): 8e - 8.
[Full Text]


Home page
J. Lipid Res.Home page
C. R. Pullinger, D. Gaffney, M. M. Gutierrez, M. J. Malloy, V. N. Schumaker, C. J. Packard, and J. P. Kane
The apolipoprotein B R3531C mutation: characteristics of 24 subjects from 9 kindreds
J. Lipid Res., February 1, 1999; 40(2): 318 - 327.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
D.-Y. Tai, J.-P. Pan, and G.-J. Lee-Chen
Identification and haplotype analysis of apolipoprotein B-100 Arg3500->Trp mutation in hyperlipidemic Chinese
Clin. Chem., August 1, 1998; 44(8): 1659 - 1665.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. Zulewski, R. Ninnis, A. R. Miserez, M. W. Baumstark, and U. Keller
VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100
J. Lipid Res., February 1, 1998; 39(2): 380 - 387.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
M.-L. Choong, E. S. C. Koay, K.-L. Khoo, M.-C. Khaw, and S. K. Sethi
Denaturing gradient-gel electrophoresis screening of familial defective apolipoprotein B-100 in a mixed Asian cohort: two cases of arginine3500 -> tryptophan mutation associated with a unique haplotype
Clin. Chem., June 1, 1997; 43(6): 916 - 923.
[Abstract] [Full Text] [PDF]